Current Status of HER2 Testing

This publication has 22 references indexed in Scilit:

• Interpretation and Quantification of Immunostains
  The American Journal of Surgical Pathology, 2001
• Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message
  Journal of Clinical Oncology, 2001
• When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer
  Journal of Clinical Oncology, 2001
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry
  Journal of Clinical Oncology, 2000
• Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast Carcinoma
  Laboratory Investigation, 2000
• HER-2/neu Testing in Breast Carcinoma: A Combined Immunohistochemical and Fluorescence In Situ Hybridization Approach
  Laboratory Investigation, 2000
• Prognostic Factors in Breast Cancer
  Archives of Pathology & Laboratory Medicine, 2000
• Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
  Journal of Clinical Oncology, 1999
• Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
  Journal of Clinical Oncology, 1999